Attendee search 

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Phyteau is developing an innovative, new class of therapeutics for diabetes, obesity, related conditions like NAFLD, NASH and prediabetes, and weight-loss. Unlike many drugs in the market today, our therapeutics are completely safe, and free of adverse side-effects.

Phyteau’s new incretin-based approach activates the body’s natural metabolic system
by triggering specialized enteroendocrine cells in the lining of the intestines to release
therapeutic levels of key hormones, including GLP-1, PYY and CCK. These boosted hormones:

1) signal insulin release,
2) reduce blood sugar levels and peaks, and HbA1c,
3) reduce appetite, food intake and weight, increase satiety,
4) slows gastric emptying and intestinal motility,
5) improve metabolism and fat thermogenesis,
6) reduce liver fat and fibrosis,
7) protect against many age-related functional declines and conditions, and
8) provide restorative and protective benefits to the cardiovascular and nervous systems and major organs

The result is safe and affordable first-line treatments that provide a powerful tool for blood sugar control, weight-loss and improving metabolism. Our technology, developed at Caltech, UCLA and Cedars Sinai Medical Center, has 3 patents awarded, 5 more pending, with more planned.

Phyteau’s deep technology platform and portfolio of agents allows us to address growing unmet global needs in a variety of markets. We have 3 pharmaceutical products in development as well as breakthrough medical and functional food products and other consumer health & nutrition products.